Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
Vogl DT, Liu SV, Chong EA, Luger SM, Porter DL, Schuster SJ, Tsai DE, Perl A, Loren AW, Goldstein SC, Nasta SD, Andreadis C, Mangan PA, Hummel K, Siegel DL, Glatstein E, Stadtmauer EA. Vogl DT, et al. Among authors: siegel dl. Am J Hematol. 2007 Dec;82(12):1071-5. doi: 10.1002/ajh.21038. Am J Hematol. 2007. PMID: 17696204 Free article.
Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma.
Andreadis C, Schuster SJ, Chong EA, Svoboda J, Luger SM, Porter DL, Tsai DE, Nasta SD, Elstrom RL, Goldstein SC, Downs LH, Mangan PA, Cunningham KA, Hummel KA, Gimotty PA, Siegel DL, Glatstein E, Stadtmauer EA. Andreadis C, et al. Among authors: siegel dl. Bone Marrow Transplant. 2005 Dec;36(11):955-61. doi: 10.1038/sj.bmt.1705178. Bone Marrow Transplant. 2005. PMID: 16205727
Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation.
Svoboda J, Andreadis C, Elstrom R, Chong EA, Downs LH, Berkowitz A, Luger SM, Porter DL, Nasta S, Tsai D, Loren AW, Siegel DL, Glatstein E, Alavi A, Stadtmauer EA, Schuster SJ. Svoboda J, et al. Among authors: siegel dl. Bone Marrow Transplant. 2006 Aug;38(3):211-6. doi: 10.1038/sj.bmt.1705416. Epub 2006 Jun 12. Bone Marrow Transplant. 2006. PMID: 16770314
Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma.
Olin RL, Vogl DT, Porter DL, Luger SM, Schuster SJ, Tsai DE, Siegel DL, Cook RJ, Mangan PA, Cunningham K, Stadtmauer EA. Olin RL, et al. Among authors: siegel dl. Bone Marrow Transplant. 2009 Mar;43(5):417-22. doi: 10.1038/bmt.2008.334. Epub 2008 Oct 13. Bone Marrow Transplant. 2009. PMID: 18850013 Free PMC article.
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.
Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, Lacey SF, Badros AZ, Garfall A, Weiss B, Finklestein J, Kulikovskaya I, Sinha SK, Kronsberg S, Gupta M, Bond S, Melchiori L, Brewer JE, Bennett AD, Gerry AB, Pumphrey NJ, Williams D, Tayton-Martin HK, Ribeiro L, Holdich T, Yanovich S, Hardy N, Yared J, Kerr N, Philip S, Westphal S, Siegel DL, Levine BL, Jakobsen BK, Kalos M, June CH. Rapoport AP, et al. Among authors: siegel dl. Nat Med. 2015 Aug;21(8):914-921. doi: 10.1038/nm.3910. Epub 2015 Jul 20. Nat Med. 2015. PMID: 26193344 Free PMC article.
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.
Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, Krevvata M, Carroll MP, Matsui WH, Wang Q, Dhodapkar MV, Dhodapkar K, Das R, Vogl DT, Weiss BM, Cohen AD, Mangan PA, Ayers EC, Nunez-Cruz S, Kulikovskaya I, Davis MM, Lamontagne A, Dengel K, Kerr ND, Young RM, Siegel DL, Levine BL, Milone MC, Maus MV, June CH. Garfall AL, et al. Among authors: siegel dl. JCI Insight. 2018 Apr 19;3(8):e120505. doi: 10.1172/jci.insight.120505. eCollection 2018 Apr 19. JCI Insight. 2018. PMID: 29669947 Free PMC article. Clinical Trial.
Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.
Garfall AL, Stadtmauer EA, Hwang WT, Lacey SF, Melenhorst JJ, Krevvata M, Carroll MP, Matsui WH, Wang Q, Dhodapkar MV, Dhodapkar K, Das R, Vogl DT, Weiss BM, Cohen AD, Mangan PA, Ayers EC, Nunez-Cruz S, Kulikovskaya I, Davis MM, Lamontagne A, Dengel K, Kerr ND, Young RM, Siegel DL, Levine BL, Milone MC, Maus MV, June CH. Garfall AL, et al. Among authors: siegel dl. JCI Insight. 2019 Feb 21;4(4):e127684. doi: 10.1172/jci.insight.127684. eCollection 2019 Feb 21. JCI Insight. 2019. PMID: 30830874 Free PMC article. No abstract available.
B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.
Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, Vogl DT, Weiss BM, Dengel K, Nelson A, Plesa G, Chen F, Davis MM, Hwang WT, Young RM, Brogdon JL, Isaacs R, Pruteanu-Malinici I, Siegel DL, Levine BL, June CH, Milone MC. Cohen AD, et al. Among authors: siegel dl. J Clin Invest. 2019 Mar 21;129(6):2210-2221. doi: 10.1172/JCI126397. J Clin Invest. 2019. PMID: 30896447 Free PMC article. Clinical Trial.
CAR T cell viability release testing and clinical outcomes: is there a lower limit?
Chong EA, Levine BL, Grupp SA, Davis MM, Siegel DL, Maude SL, Gladney WL, Frey NV, Porter DL, Hwang WT, Chong ER, June CH, Schuster SJ. Chong EA, et al. Among authors: siegel dl. Blood. 2019 Nov 21;134(21):1873-1875. doi: 10.1182/blood.2019002258. Blood. 2019. PMID: 31554634 Free PMC article. No abstract available.
121 results